Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of CFZ533 in Healthy Subjects and Rheumatoid Arthritis Patients
NCT02089087Phase 1Completed
- Sponsor
- Novartis
- Start
- Jan 2013
- Primary completion
- Feb 2017
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of iscalimab in rheumatoid arthritis (RA) (3 arms), sponsored by Novartis. Primary endpoint: Number of patients with adverse events as a measure of safety and tolerability at 7 months. Started Jan 2013; status: completed.
02
Drugs
iscalimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02089087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02089087.